Prescription Drug Monitoring Programs

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Prescription Drug Monitoring Programs"

Transcription

1 Prescription Drug Monitoring Programs Montana State Fund 13 th Annual Medical Conference November 1, 2013 Peter Kreiner, Ph.D. PDMP Center of Excellence at Brandeis University

2 Primary non-heroin opiates/synthetics admission rates, by State (per 100,000 population aged 12 and over) 2

3 Primary non-heroin opiates/synthetics admission rates, by State (per 100,000 population aged 12 and over) 3

4 Primary non-heroin opiates/synthetics admission rates, by State (per 100,000 population aged 12 and over) 4

5 Primary non-heroin opiates/synthetics admission rates, by State (per 100,000 population aged 12 and over) 5

6 Primary non-heroin opiates/synthetics admission rates, by State (per 100,000 population aged 12 and over) 6

7 Primary non-heroin opiates/synthetics admission rates, by State (per 100,000 population aged 12 and over) 7

8 Overview What are prescription drug monitoring programs (PDMPs) and how can they help? A quick aside: Why is the evidence base for PDMPs so limited? Selected best and promising practices of PDMPs Using identified PDMP data Using de-identified PDMP data

9 What Data Fields Does PDMP Data Contain? Patient first and last name, street address, town/city, Zip Code, birth date, gender Prescriber and pharmacy DEA license #, street address, town/city, Zip Code Prescription information: date prescribed, date filled, drug name, drug NDC code, dosage, days supply, source of payment

10 System Overview Pharmacists Reports Sent Reports Sent Dispensers State PDMP Data Submitted Reports Sent Prescribers *Other groups may also receive reports other than those listed Law Enforcement & Professional Licensing Agencies

11 60 Number of Prescription Drug Monitoring Programs (PDMPs): Authorizing Legislation Passed Between 1939 and PDMPs Number of PDMPs Years

12 Why Is the Evidence Base So Limited? Nearly half of currently operational state PDMPs become so since 2008 (21 out of 46 = 46%) 13 PDMPs (28%) became operational since 2011 Limited years for studying effects Great variation in characteristics across PDMPs Difficulty in separating out PDMP effects

13 PDMP Characteristics Location of PDMP in state government Health dept., board of pharmacy, single state authority Law enforcement agency Professional licensing board No. of states Drugs that can be monitored No. of states Only Schedule II drugs 1 Only Schedule II and III drugs Schedule II, III, and IV drugs 2 45 Schedule II V drugs 29 Source: National Alliance for Model State Drug Laws

14 PDMP Characteristics II Access to law enforcement No. of states Access other than to law enforcement No. of states For probable cause, search warrant, subpoena, other judicial process Pursuant to active investigation On request from law enforcement To prescribers and dispensers To patient, parent, or guardian To licensing or regulatory boards To Medicare, Medicaid, or state insurance programs

15 PDMP Characteristics III Frequency of pharmacy submission of data to PDMPs No. of states Real-time data submission 1 Weekly data submission 22 Monthly data submission 6 No provision for electronic submission 4

16 PDMP Characteristics IV Interstate data sharing Share data with other PDMPs Share with users in other states Share with both other PDMPs and authorized users No. of states Provide unsolicited reports No. of states No reports 7 To prescribers only 2 To law enforcement only 2 To prescribers and pharmacists only To prescribers, pharmacists, law enforcement, and licensing entities 5 20

17 Nevertheless, Some Suggestive Within-State Evidence

18 Multiple provider episode rates* for CS II drugs, Quarter 4 of 2011 vs. Quarter 4 of 2012, Florida Rate per 100,000 residents < Age Group Q Q *Having CSII rx from 5+ prescribers dispensed at 5+ pharmacies during one quarter. 18

19 Florida s PDMP Continued The PDMP became operational in September, 2011 The law authorizing the PDMP was accompanied by several other provisions: A requirement for pain clinics to register with the state Increased penalties for operating a pill mill Drug overdose deaths associated with Schedule II opioids declined in 2012 from 2011 Oxycodone: 33%; Oxymorphone: 35%

20 Selected PDMP Best Practices Unsolicited reporting to providers Interstate data sharing with other PDMPs Weekly or more frequent data submission Use of PDMP data for surveillance and to support prevention (de-identified data)

21 Numbers of histories Notes from the Field : Wyoming PDMP Unsolicited Prescription Histories per Month, 10/2008 9/ Numbers of histories Solicited Prescription Histories per Month, 10/2008 9/ Source: Wyoming PDMP Source: Wyoming PDMP

22 Why Unsolicited Reports Are Important MA PDMP survey physicians receiving unsolicited reports: Only 8% of respondents were aware of all or most of other prescribers Only 9% said based on current knowledge, including PDMP report, patient appears to have legitimate medical reason for prescriptions from multiple prescribers Alert prescribers of persons receiving more than 100 mg morphine equivalents of opioids per day 8.9 times higher risk of death than low dose

23 Massachusetts: Evaluation of Unsolicited Reporting MA initiated unsolicited reporting in 2010 Schedule II only Unsolicited reports sent on a small fraction of patients who met questionable activity threshold We constructed profiles of patients on whom reports were sent and developed a comparison group (on whom reports not sent) based on propensity score matching Intervention and comparison groups matched on age, gender, and # prescriptions, # prescribers, # pharmacies in the 12 months prior to sending of reports Both groups tracked for subsequent 12 months in PDMP data

24 Massachusetts: Evaluation of unsolicited reporting Preliminary results Case Group (N = 84) Comparison Group (N = 84) Pre Post % Change Pre Post % Change Probability Total # of Schedule II Rx Average # of Prescribers Average # of Pharmacies Average Dosage Units ,309 1, ,428 1, Average days Supply

25 Interstate Data Sharing All PDMPs receive data on prescriptions written in every other state and filled in their state 3 hubs currently enable provider access to patient prescription history data from multiple state PDMPs Interstate sharing varies: Provider requests for data from other states mostly focus on neighboring states More comprehensive data should lead to better clinical decision-making, but no evidence as yet

26 Weekly or More Frequent Data Submission: Physician Use of PDMP Data OH study of Emergency Department 41% of prescribers who received PMP report altered prescribing for patients receiving multiple simultaneous narcotics prescriptions Of these providers, 63% prescribed no narcotics or fewer 39% prescribed more For non-ed physicians, need for data frequency not as clear

27 Use of PDMP Data for Surveillance and to Support Prevention: Massachusetts

28 2005 Opioid-related Health Overdose Problems Rate per 100,000 by Town Rate per 100,000 Quintiles

29 2005 Prescriptions Associated with Questionable Activity (Rates per 100,000 Prescriptions) by Pharmacy Town Questionable activity rates

30 Massachusetts Geospatial Analysis Do rates of questionable activity predict subsequent changes in rates of opioid overdoses at the community level? Controlling for community socio-demographic variables and for spatial association

31 Spatial regression: questionable activity rate as a predictor of subsequent change in opioid overdose rate (Data from Massachusetts PDMP in partnership with Brandeis University) Variable Coefficient Probability Constant Opioid OD rate average.519 <.001 Population density <.001 Poverty rate Ethnic heterogeneity Population mobility Percent > Questionable activity rate average.226 <.001 Nonprofit intensity <.001 Spatial lag (Opioid OD rate average) Lambda (spatial association error term) Dependent variable: Opioid OD rate average Pseudo R-squared:.699

32 Implications Highlights importance of PDMP-based measures for surveillance Questionable activity measure predicts subsequent increases in rates of overdoses Timeliness of PDMP data compared to health outcome data Importance of PDMP-based measures for prevention Identify areas at high risk for increase in opioid overdoses Identify clusters of communities at high risk: targeting cluster for intervention may be more effective Identify low-risk islands amidst high-risk communities: what can be learned from them?

33 Other Surveillance Applications Examine prescribing rates in different states/regions and over time Broken out by age groups and gender Examine (trends in) measures of risky patient and provider behavior Examine geographic variation and factors associated with this variation

34 Rate per 1,000 residents Opioid prescription rates by age group, Florida and Maine, ,400 1,200 1, Florida Maine 0 < Age Group 34

35 Daily opioid dosage in MME and high dosage by quarter, Florida, Percent and MME/day MME/day % > 100 MME/day 0 Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Quarter/Year Q3 12 Q4 12 Note: First 3 quarters of 2011 data is incomplete and should be interpreted with caution. 35

36 Percent of prescriptions accounted for by prescriber decile by CS type, Florida, 2012 Percent Prescriber Deciles Opioid Benzodiazepine Stimulant 36

37 Mean daily opioid dosage by prescriber decile by quarter, Florida, Q to Q Mean daily dosage (MME) % Top Fifth Tenth TOTAL 0 Q Q Q Q Q Calendar Quarter Prescriber deciles are based on number of opioid prescriptions. 37

38 Percent of a prescriber s patients seeing multiple providers by distance deciles, Florida, 2012 Percent Prescriber Distance Deciles Mean miles to prescriber. Prescribers are divided into deciles according to the mean distance between them and their patients for all CS prescriptions. Multiple providers means 5+ prescribers and 5+ pharmacies in 3 months. Includes out of state residents. 38

39 New and Promising Practices Collect ID of person picking up prescription Mandatory provider registration with and use of PDMP Batch data sharing with 3 rd party payers (Medicare, Medicaid, public Workers Comp) Interoperability of PDMP data with health information exchanges, electronic health record systems, pharmacy dispensing software Evaluate prescriber education initiatives

40 Collect ID of Person Picking Up Prescription Require pharmacies: To do photo ID check before dispensing a controlled substance Rx to verify who has the drug To submit ID information on who picks-up each prescription -- so PDMP knows who actually has the drug MA PDMP has mandated such reporting and positive ID for Schedule II prescriptions since 1/2/2009 MA found 38% of the persons who dropped off or picked up the prescriptions are not the patient As of 1/1/2011, MA requires reporting and positive ID for all Schedule II to V prescriptions

41 Mandatory Provider Registration and Use Recently begun in Kentucky (July, 2012) Provider must check PDMP at: First C-II or C-III hydrocodone prescription or change in drug Continued prescribing of these Rx at three months Average weekday requests to KASPER: Before mandate -- 2,900 After mandate -- 19,000 Legislation passed in three other states (MA, NY, TN), in process of being implemented No evidence as yet of effects on patient care and outcomes

42 Batch Data Sharing with 3 rd Party Payers Most PDMPs allow Medicare, Medicaid, and/or state insurance programs to access PDMP data on individual patients WA PDMP first example of batch data sharing, with Medicaid agency and state Workers Comp agency > 2,000 Medicaid patients were found to have obtained prescriptions using both Medicaid and cash on the same day in 2012

43 Interoperability of PDMPs with HIEs, EHRs, Pharmacy Dispensing Software The Substance Abuse and Mental Health Services Administration (SAMHSA) has recently awarded grants to 9 state PDMPs to improve interoperability: Integrate PDMP data into EHRs (e.g., for hospital ED) and in pharmacy dispensing software Many of these projects build on earlier pilot studies conducted by MITRE Cross-site evaluation by the Centers for Disease Control and Prevention

44 Evaluate Prescriber Education Initiatives Many efforts underway nationwide to influence prescriber behavior The FDA has engaged PDMP Center of Excellence to inventory these efforts and summarize the evidence base PDMP data can be used to evaluate whether desired changes in prescriber behavior have occurred Population-based evaluation only is possible, since PDMP data contain no medical information

45 PDMP Center of Excellence White Paper on PDMP Best and Promising Practices Available at: eports/pdmp_full%20and%20final.pdf

46 Contact Information Peter Kreiner, Ph.D. Principal Investigator PDMP Center of Excellence Brandeis University

Prescription Drug Monitoring Programs: Adopting Best & Promising PDMP Practices

Prescription Drug Monitoring Programs: Adopting Best & Promising PDMP Practices Prescription Drug Monitoring Programs: Adopting Best & Promising PDMP Practices National Governors Association Policy Academy: Reducing Prescription Drug Abuse June 8, 2015 Burlington, VT Improving Interstate

More information

A New Generation of Prescription Monitoring Programs: Best & Promising Practices

A New Generation of Prescription Monitoring Programs: Best & Promising Practices A New Generation of Prescription Monitoring Programs: Best & Promising Practices National PDMP Meeting Washington, DC September 25, 2013 Presented by John L Eadie Why Is a New Generation of PDMPs Being

More information

Maximizing Use of Prescription Drug Monitoring Programs

Maximizing Use of Prescription Drug Monitoring Programs Maximizing Use of Prescription Drug Monitoring Programs Christopher M..Jones, PharmD, MPH Division of Unintentional Injury Prevention National Center for Injury Prevention and Control Centers for Disease

More information

COMPILATION OF STATE PRESCRIPTION MONITORING PROGRAM MAPS

COMPILATION OF STATE PRESCRIPTION MONITORING PROGRAM MAPS MTION OF STATE PREPTION NITONG PROGRAM PS This project was supported by Cooperative Agreement No. 202-DC-BX-K002 awarded by the Bureau of Justice Assistance. The Bureau of Justice Assistance is a component

More information

Washington. Contact Information. Email: Statistics. Technological Capabilities

Washington. Contact Information. Email: Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Baumgartner, Chris - Director P O Box 47852 Olympia WA 98504-7852 Office: (360) 236-4806 Fax: (360) 236-2901 Email: Washington Washington

More information

Delaware. Division of Professional Regulation, Office of Controlled Substances Professional Licensing Agency

Delaware. Division of Professional Regulation, Office of Controlled Substances Professional Licensing Agency PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Delaware Division of Professional Regulation, Office of Controlled Substances Professional Licensing Agency Nettesheim, Samantha -

More information

Georgia. Contact Information. Office: Fax: Email: Statistics. Technological Capabilities

Georgia. Contact Information. Office: Fax: Email: Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Higgins, Ronnie - Special Agent 40 Pryor St SW, Ste 2000 Atlanta GA 30303 Office: (404) 656-5100 Fax: (404) 651-8210 Email: rhiggins@gdna.ga.gov

More information

2015 ANNUAL REVIEW OF PRESCRIPTION MONITORING PROGRAMS

2015 ANNUAL REVIEW OF PRESCRIPTION MONITORING PROGRAMS 2015 ANNUAL REVIEW OF PRESCRIPTION MONITORING PROGRAMS Research current through September 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy.

More information

New Mexico. Contact Information. Email: Statistics. Technological Capabilities

New Mexico. Contact Information. Email: Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Vacant - PMP Director 5500 San Antonio Drive NE Albuquerque NM 87109 Office: (505) 222-9837 Fax: (505) 222-9845 Email: @state.nm.us

More information

Bureau of Justice Assistance. Prescription Drug Monitoring Program Performance Measures Report: January 2009 through June 2012

Bureau of Justice Assistance. Prescription Drug Monitoring Program Performance Measures Report: January 2009 through June 2012 Bureau of Justice Assistance Prescription Drug Monitoring Program Performance Measures Report: January 2009 through Revised October 21, 2013 Grantee Feedback Included April 4, 2014 Prepared by Peter Kreiner,

More information

Massachusetts. Contact Information. Statistics. Technological Capabilities

Massachusetts. Contact Information. Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Vacant - Assistant Director 99 Chauncy Street Boston MA 02111 Office: (617) 753-8104 Fax: (617) 524-8062 Email: ASAP Versions Accepted

More information

Colorado Prescription Drug Monitoring Program. Department of Regulatory Agencies Division of Professions and Occupations State Board of Pharmacy

Colorado Prescription Drug Monitoring Program. Department of Regulatory Agencies Division of Professions and Occupations State Board of Pharmacy Colorado Prescription Drug Monitoring Program Department of Regulatory Agencies Division of Professions and Occupations State Board of Pharmacy DORA is dedicated to preserving the integrity of the marketplace

More information

Idaho. Contact Information. Fax: (208) 334-3536 Email: Statistics. Technological Capabilities

Idaho. Contact Information. Fax: (208) 334-3536 Email: Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Idaho Board of Pharmacy Pharmacy Board http://idaho.pmpaware.net pmp@bop.idaho.gov Anderson, Teresa - Program Information Coordinator

More information

Arizona. Contact Information. Office: Fax: Email: Statistics. Technological Capabilities

Arizona. Contact Information. Office: Fax: Email: Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Arizona State Board of Pharmacy Pharmacy Board Wright, Dean - Program Director P O Box 18520 Phoenix AZ 85005 Office: (602) 771-2744

More information

For a Healthier America: Reducing Prescription Drug Misuse and Abuse

For a Healthier America: Reducing Prescription Drug Misuse and Abuse For a Healthier America: Reducing Prescription Drug Misuse and Abuse The misuse and abuse of prescription medicines is a growing public health problem. In addition to the tragic toll on families and communities,

More information

South Carolina. South Carolina Department of Health and Environmental Control Department of Health http://www.scdhec.gov/scripts scripts@dhec.sc.

South Carolina. South Carolina Department of Health and Environmental Control Department of Health http://www.scdhec.gov/scripts scripts@dhec.sc. PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Frick, Christie J. - Director (Rph) 2600 Bull St Columbia SC 29201 Office: (803) 896-0688 Fax: (803) 896-0686 Email: SCRIPTS frickcj@dhec.sc.gov

More information

Harold Rogers Prescription Drug Monitoring Program

Harold Rogers Prescription Drug Monitoring Program Harold Rogers Prescription Drug Monitoring Program 19 th National Conference on Pharmaceutical and Chemical Diversion June 16-17, 2010 Harold Rogers Prescription Drug Monitoring Program Since fiscal year

More information

Mandating PDMP participation by medical providers: current status and experience in selected states

Mandating PDMP participation by medical providers: current status and experience in selected states Prescription Drug Monitoring Program Center of Excellence at Brandeis COE Briefing Mandating PDMP participation by medical providers: current status and experience in selected states Revision 1, February

More information

Massachusetts Substance Abuse Policy and Practices. Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District

Massachusetts Substance Abuse Policy and Practices. Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District Massachusetts Substance Abuse Policy and Practices Senator Jennifer L. Flanagan Massachusetts Worcester and Middlesex District November 2014 Substance Abuse and Addiction National and State opioid abuse

More information

Maryland. Department of Health and Mental Hygiene, Alcohol and Drug Abuse Administration Substance Abuse Agency

Maryland. Department of Health and Mental Hygiene, Alcohol and Drug Abuse Administration Substance Abuse Agency PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Jackson, Kate - PDMP Manager 55 Wade Ave Catonsville MD 21228 Office: (410) 402-8609 Fax: (410) 402-8601 Email: Maryland Department

More information

Illinois. Contact Information. Office: Fax: Email: Statistics. Technological Capabilities

Illinois. Contact Information. Office: Fax: Email: Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Berberet, Craig - PMP Manager 401 N Fourth St, Rm 126 Springfield IL 62702 Office: (217) 558-0943 Fax: (217) 557-7975 Email: PIL Department

More information

DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services. NEW products from the Medicare Learning Network (MLN)

DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services. NEW products from the Medicare Learning Network (MLN) Medicare Advantage Outreach and Education Bulletin Anthem Blue Cross Prescription Drug Monitoring Programs Prescription drug abuse and diversion are acute problems in the area of pain management. The Centers

More information

Florida. http://www.floridahealth.gov/statistics-and-data/e-forcse/index.html e-forcse@flhealth.gov. Contact Information. Fax: Email: Statistics

Florida. http://www.floridahealth.gov/statistics-and-data/e-forcse/index.html e-forcse@flhealth.gov. Contact Information. Fax: Email: Statistics PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Florida Department of Health Department of Health Florida http://www.floridahealth.gov/statistics-and-data/e-forcse/index.html e-forcse@flhealth.gov

More information

The Administration s Response to the Prescription Drug Epidemic: Action Items

The Administration s Response to the Prescription Drug Epidemic: Action Items The Administration s Response to the Prescription Drug Epidemic: Action Items As outlined in Epidemic: Responding to America s Prescription Drug Abuse Crisis, below are the action items identified in the

More information

Controlled Substance Prescribing Laws, The Prescription Monitoring Program, and Preventing Drug Diversion

Controlled Substance Prescribing Laws, The Prescription Monitoring Program, and Preventing Drug Diversion Controlled Substance Prescribing Laws, The Prescription Monitoring Program, and Preventing Drug Diversion Michael Halse, PharmD PGY1 Resident Pharmacist South County Hospital and Healthcare System Disclosures

More information

Montana. Contact Information. Email: Statistics. Technological Capabilities

Montana. Contact Information. Email: Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Montana Board of Pharmacy Pharmacy Board www.mpdr.mt.gov dlibsdmpdr@mt.gov Peterson, Donna - Program Manager PO Box 200513 Helena MT

More information

Colorado. Contact Information. Statistics. Technological Capabilities

Colorado. Contact Information. Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Colorado State Board of Pharmacy Pharmacy Board http://www.hidinc.com/copdmp pdmpinqr@state.co.us Rivera, Janina - PDMP Administrator

More information

Prescription Drug Monitoring Program Center of Excellence at Brandeis

Prescription Drug Monitoring Program Center of Excellence at Brandeis Prescription Drug Monitoring Program Center of Excellence at Brandeis Notes from the Field NF 4.1 Using PDMPs to Improve Medical Care: Washington State s Data Sharing Initiative with Medicaid and Workers

More information

New Jersey. Contact Information. Statistics. Technological Capabilities

New Jersey. Contact Information. Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Mielo, James - Administrator 124 Halsey St Newark NJ 07102 Office: (973) 273-8010 Fax: Email: NJPMRS mieloj@dca.lps.state.nj.us ASAP

More information

Preliminary Evaluation of the Prescription Drug Monitoring Program

Preliminary Evaluation of the Prescription Drug Monitoring Program Preliminary Evaluation of the Prescription Drug Monitoring Program Recommendations: Waive from full evaluation Extend termination date by three years to July 1, 2019 Require follow-up report by January

More information

2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov

2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov OHIO AUTOMATED RX REPORTING SYSTEM 2015 REPORT Steven W. Schierholt, Esq. Executive Director www.pharmacy.ohio.gov OHIO AUTOMATED RX REPORTING SYSTEM What is OARRS? To address the growing misuse and diversion

More information

PRESCRIPTION PAINKILLER OVERDOSES

PRESCRIPTION PAINKILLER OVERDOSES IMPACT{ POLICY PRESCRIPTION PAINKILLER OVERDOSES National Center for Injury Prevention and Control Division of Unintentional Injury Prevention What s the Issue? In a period of nine months, a tiny Kentucky

More information

2010-2011 Prescription Drug Monitoring Program Annual Report

2010-2011 Prescription Drug Monitoring Program Annual Report 2010-2011 Prescription Drug Monitoring Program Annual Report Prescription Drug Monitoring Program E-FORCSE 4052 Bald Cypress Way, Bin C-16 Tallahassee, FL 32399 (850) 245-4444 X 3700 December 1, 2011 Prescription

More information

Prescription Opioid Use and Opioid-Related Overdose Death TN, 2009 2010

Prescription Opioid Use and Opioid-Related Overdose Death TN, 2009 2010 Prescription Opioid Use and Opioid-Related Overdose Death TN, 2009 2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence Service Officer Tennessee Department of

More information

Prescription Drug Monitoring Program Administrators Guide for Training Law Enforcement

Prescription Drug Monitoring Program Administrators Guide for Training Law Enforcement Prescription Drug Monitoring Program Administrators Guide for Training Law Enforcement 2013 Telephone: (781) 609-7741 Fax: (888) 705-8053 Email: info@pdmpassist.org Website: www.pdmpassist.org INTRODUCTION

More information

Pennsylvania s ABC-MAP Program

Pennsylvania s ABC-MAP Program Pennsylvania s ABC-MAP Program Recommendations on Best Practices ABC-MAP Governance Board Meeting May 20, 2015 Brandon C. Maughan, MD, MHS Marcus A. Bachhuber, MD University of Pennsylvania Philadelphia

More information

The Prescrip+on Drug Abuse Epidemic and Preven+on: How Prescrip+on Monitoring Programs Can Help

The Prescrip+on Drug Abuse Epidemic and Preven+on: How Prescrip+on Monitoring Programs Can Help The Prescrip+on Drug Abuse Epidemic and Preven+on: How Prescrip+on Monitoring Programs Can Help PMP Center of Excellence at Brandeis University September 23, 2010 Webinar Learning Objec+ves To understand

More information

Drug Diversion. Controlled Substance Prescribing and Diversion

Drug Diversion. Controlled Substance Prescribing and Diversion Drug Diversion Provider Presentation Controlled Substance Prescribing and Diversion Angela Wallace, R.Ph. Coastal District Inspector, PMP Law Enforcement Officer DHEC Bureau of Drug Control Presentation

More information

American Indian Health Commission for Washington State October 1, 2015

American Indian Health Commission for Washington State October 1, 2015 American Indian Health Commission for Washington State October 1, 2015 States with more opioid pain reliever sales tend to have more drug overdose deaths Death rate, 2011, National Vital Statistics System.

More information

Prescribers required to check PDMP before first prescription for Controled Substances for new patient.

Prescribers required to check PDMP before first prescription for Controled Substances for new patient. State, District, or Territory Alabama Arizona Arkansas Colorado Connecticut Delaware Georgia Guam Criteria for Mandatory Enrollment or Query of PDMP Before renewing an Alabama Controlled Substances Certificate,

More information

Guam. Contact Information. Email: Statistics. Technological Capabilities

Guam. Contact Information. Email: Statistics. Technological Capabilities PDMP name: Agency Responsible: Agency Type: PDMP Website: PDMP Email: Naval, Cynthia L. - Planner IV 123 Chalan Kareta Mangilao GU 96913-6304 Office: (671) 735-7204 Fax: (671) 734-5556 Email: GPDMP Guam

More information

Prescription Drug Abuse Florida s Health Crisis

Prescription Drug Abuse Florida s Health Crisis Prescription Drug Abuse Florida s Health Crisis Overview Florida has been the epicenter for the diversion and abuse of prescription drugs. Prescription drugs killed almost 7 Floridians per day after an

More information

The Opioid Addiction Epidemic: How marketing and regulatory failure led to a public health crisis

The Opioid Addiction Epidemic: How marketing and regulatory failure led to a public health crisis The Opioid Addiction Epidemic: How marketing and regulatory failure led to a public health crisis Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation Inc. Executive Director, Physicians

More information

Prescription Drug Monitoring Programs: Evaluation of Effectiveness

Prescription Drug Monitoring Programs: Evaluation of Effectiveness Prescription Drug Monitoring Programs: Evaluation of Effectiveness Eric Lavonas, MD Associate Director, Rocky Mountain Poison and Drug Center Denver Health and Hospital Authority Associate Professor, Department

More information

History of Prescription Drug Monitoring Programs. PDMP Training and Technical Assistance Center Brandeis University

History of Prescription Drug Monitoring Programs. PDMP Training and Technical Assistance Center Brandeis University History of Prescription Drug Monitoring Programs PDMP Training and Technical Assistance Center Brandeis University History of Prescription Drug Monitoring Programs First PDMP Early PDMP Characteristics

More information

Bureau of Justice Assistance Harold Rogers Prescription Drug Monitoring Program National Meeting 9/23/2014

Bureau of Justice Assistance Harold Rogers Prescription Drug Monitoring Program National Meeting 9/23/2014 Bureau of Justice Assistance Harold Rogers Prescription Drug Monitoring Program National Meeting 9/23/2014 Jeanne Tuttle, R.Ph. National Pharmacist Program Managers Pharmacy Benefits Management Services

More information

Enhancing Access to Prescription Drug Monitoring Programs

Enhancing Access to Prescription Drug Monitoring Programs Enhancing Access to Prescription Drug Monitoring Programs Pilot Impact, In Their Own Words Approved for Public Release: 13-1097. Distribution Unlimited. 2013 The MITRE Corporation. All rights reserved.

More information

Mandatory Prescriber Usage of the Kentucky All Schedule Prescription Electronic Reporting System (KASPER)

Mandatory Prescriber Usage of the Kentucky All Schedule Prescription Electronic Reporting System (KASPER) Mandatory Prescriber Usage of the Kentucky All Schedule Prescription Electronic Reporting System (KASPER) David R. Hopkins KASPER Program Manager Office of Inspector General Kentucky Cabinet for Health

More information

SAMHSA Initiatives to Educate Prescribers and Consumers and Treatment Resources

SAMHSA Initiatives to Educate Prescribers and Consumers and Treatment Resources SAMHSA Initiatives to Educate Prescribers and Consumers and Treatment Resources Nick Reuter Division of Pharmacologic Therapy Substance Abuse and Mental Health Services Administration 1 Overview National

More information

Briefing on PDMP Effectiveness

Briefing on PDMP Effectiveness Prescription Drug Monitoring Program Center of Excellence at Brandeis Briefing on PDMP Effectiveness Updated September 2014 This project was supported by Grant No. 2011-PM-BX-K002 awarded by the Bureau

More information

The Prescription Drug Abuse and Heroin Crisis: New York s Response

The Prescription Drug Abuse and Heroin Crisis: New York s Response The Prescription Drug Abuse and Heroin Crisis: New York s Response Joshua S. Vinciguerra, Director Bureau of Narcotic Enforcement October 28, 2015 October 28, 2015 2 The Connection States with more opioid

More information

Options for Unsolicited Reporting

Options for Unsolicited Reporting Prescription Drug Monitoring Program Center of Excellence at Brandeis Guidance on PDMP Best Practices BP 01 Options for Unsolicited Reporting January, 2014 This project was supported by Grant No. 2011-PM-BX-K002

More information

RESPONSE TO THE MASSACHUSETTS OPIOID PRESCRIPTION DRUG EPIDEMIC

RESPONSE TO THE MASSACHUSETTS OPIOID PRESCRIPTION DRUG EPIDEMIC RESPONSE TO THE MASSACHUSETTS OPIOID PRESCRIPTION DRUG EPIDEMIC 2014 Report of Best Practices Joint Policy Working Group With the goal of reducing diversion, abuse and addiction and protecting access for

More information

Data-Driven Multi-Disciplinary Approaches to Reducing Rx Abuse, BJA Award FY 2014

Data-Driven Multi-Disciplinary Approaches to Reducing Rx Abuse, BJA Award FY 2014 Data-Driven Multi-Disciplinary Approaches to Reducing Rx Abuse, BJA Award FY 2014 Denise Paone and Alexandra Harocopos Bureau of Alcohol & Drug Use Prevention, Care & Treatment New York City Department

More information

Substance Use: Addressing Addiction and Emerging Issues

Substance Use: Addressing Addiction and Emerging Issues MODULE 6: SUBSTANCE USE: ADDRESSING ADDICTION AND EMERGING ISSUES Substance Use: Addressing Addiction and Emerging Issues Martha C. Romney, RN, MS, JD, MPH Assistant Professor Jefferson School of Population

More information

The Massachusetts Prescription Monitoring Program

The Massachusetts Prescription Monitoring Program The Massachusetts Prescription Monitoring Program A Report to the Massachusetts General Court February 2015 Governor Charles D. Baker Secretary of Health and Human Services Marylou Sudders Massachusetts

More information

CDC Initiatives & Priorities to Address the Prescription Drug Overdose Crisis

CDC Initiatives & Priorities to Address the Prescription Drug Overdose Crisis CDC Initiatives & Priorities to Address the Prescription Drug Overdose Crisis Grant Baldwin, PhD, MPH February 2, 2016 National Center for Injury Prevention and Control Division of Unintentional Injury

More information

PRESCRIPTION DRUG ABUSE, ADDICTION AND DIVERSION: OVERVIEW OF STATE LEGISLATIVE AND POLICY INITIATIVES A THREE PART SERIES

PRESCRIPTION DRUG ABUSE, ADDICTION AND DIVERSION: OVERVIEW OF STATE LEGISLATIVE AND POLICY INITIATIVES A THREE PART SERIES PRESCRIPTION DRUG ABUSE, ADDICTION AND DIVERSION: OVERVIEW OF STATE LEGISLATIVE AND POLICY INITIATIVES A THREE PART SERIES PART 1: STATE PRESCRIPTION DRUG MONITORING PROGRAMS (PMPS) PREPARED BY THE NATIONAL

More information

JAN 2 7 2016. poisonings, commonly referred to as drug overdoses, are one of. the leading causes of injury-related mortality in Hawaii.

JAN 2 7 2016. poisonings, commonly referred to as drug overdoses, are one of. the leading causes of injury-related mortality in Hawaii. THE SENATE TWENTY-EIGHTH LEGISLATURE, 0 STATE OF HAWAII JAN 0 A BILL FOR AN ACT S.B. NO. % RELATING TO DRUG OVERDOSE PREVENTION BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII: 0 SECTION. The legislature

More information

11/26/2012. Implementation of Florida s PDMP. Disclosure

11/26/2012. Implementation of Florida s PDMP. Disclosure Implementation of Florida s PDMP Rebecca R. Poston Program Manager December 1, 2012 Disclosure I have no vested interest in or affiliation with any corporate organizations offering financial support or

More information

Connecting Prescribers and Dispensers to PDMPs through Health IT: Six Pilot Studies and Their Impact

Connecting Prescribers and Dispensers to PDMPs through Health IT: Six Pilot Studies and Their Impact Page 1 Introduction Prescription drug misuse and overdose is one of the fastest growing health epidemics in the United States. To address the prescription drug abuse problem, many states have established

More information

Briefing on PDMP Effectiveness

Briefing on PDMP Effectiveness Prescription Drug Monitoring Program Center of Excellence at Brandeis Briefing on PDMP Effectiveness Updated April 2013 This project was supported by Grant No. 2011-PM-BX-K002 awarded by the Bureau of

More information

VIRGINIA DEPARTMENT OF HEALTH PROFESSIONS VIRGINIA PRESCRIPTION MONITORING PROGRAM MINUTES OF ADVISORY PANEL

VIRGINIA DEPARTMENT OF HEALTH PROFESSIONS VIRGINIA PRESCRIPTION MONITORING PROGRAM MINUTES OF ADVISORY PANEL DRAFT VIRGINIA DEPARTMENT OF HEALTH PROFESSIONS VIRGINIA PRESCRIPTION MONITORING PROGRAM MINUTES OF ADVISORY PANEL Wednesday, September 30, 2015 9960 Mayland Drive, Suite 300 Henrico, Virginia 23233-1463

More information

Drug overdose death rates by state per 100,000 people (2008) SOURCE: National Vital Statistics System, 2008

Drug overdose death rates by state per 100,000 people (2008) SOURCE: National Vital Statistics System, 2008 PRESCRITPION DRUG ABUSE: AN EPIDEMIC What is Addiction? By: Lon R. Hays, M.D., M.B.A. Professor and Chairman Department of Psychiatry University of Kentucky Healthcare Addiction is a primary, chronic disease

More information

State Advocacy Guide to Prescription Drug Monitoring Program Legislation and Regulations

State Advocacy Guide to Prescription Drug Monitoring Program Legislation and Regulations State Advocacy Guide to Prescription Drug Monitoring Program Legislation and Regulations There is currently an epidemic of prescription opioid abuse, misuse and diversion in the U.S. Numerous federal,

More information

MA Prescription Monitoring Program Prescriber Electronic Alert Notifications

MA Prescription Monitoring Program Prescriber Electronic Alert Notifications MA Prescription Monitoring Program Prescriber Electronic Alert Notifications Bureau of Health Care Safety and Quality Len Young, Epidemiologist February 20, 2014 Slide 1 MA PRESCRIPTION MONITORING PROGRAM

More information

OBJECTIVES. ! Understand the rising epidemic of prescription drug abuse in Wyoming. ! Know how to access and use reports from the WORx program

OBJECTIVES. ! Understand the rising epidemic of prescription drug abuse in Wyoming. ! Know how to access and use reports from the WORx program Full source: Wyoming Survey & Analysis Center (2013). Wyoming Prevention Needs Assessment: Interactive Graphing. Laramie, WY: University of Wyoming. (http://pnasurvey.org) Full Source: Wyoming Department

More information

Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015

Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015 Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015 ABC-MAP Board Meeting Agenda Prescription Drug Monitoring Background ABC-MAP Overview Board Responsibilities

More information

PRESCRIPTION MONITORING PROGRAM STATE PROFILES LOUISIANA

PRESCRIPTION MONITORING PROGRAM STATE PROFILES LOUISIANA PRESCRIPTION MONITORING PROGRAM STATE PROFILES LOUISIANA Research current through July 2014. This project was supported by Grant No. G1399ONDCP03A, awarded by the Office of National Drug Control Policy.

More information

FACT SHEET FOR HEALTH CARE PRACTITIONERS

FACT SHEET FOR HEALTH CARE PRACTITIONERS Florida s Prescription Drug Monitoring Program http://www.e-forcse.com FACT SHEET FOR HEALTH CARE PRACTITIONERS The Florida Prescription Drug Monitoring Program (PDMP), known as E-FORCSE (Electronic- Florida

More information

CONNECTING FOR IMPACT: Federal Efforts to Integrate Health IT and PDMPs to Improve Patient Care

CONNECTING FOR IMPACT: Federal Efforts to Integrate Health IT and PDMPs to Improve Patient Care CONNECTING FOR IMPACT: Federal Efforts to Integrate Health IT and PDMPs to Improve Patient Care Jinhee Lee, PharmD Substance Abuse and Mental Health Services Administration Jennifer Frazier, MPH Office

More information

Prescription drug abuse trends. Minnesota s Prescription Monitoring Program. Minnesota Rural Health Conference June 25, 2013 Duluth

Prescription drug abuse trends. Minnesota s Prescription Monitoring Program. Minnesota Rural Health Conference June 25, 2013 Duluth Prescription drug abuse trends Minnesota s Prescription Monitoring Program Carol Falkowski Drug Abuse Dialogues www.drugabusedialogues.com Barbara Carter, Manager MN Board of Pharmacy www.pmp.pharmacy.state.mn.us

More information

Prescription Drug Monitoring Programs: A State Policy to Address Prescription Opioid Poisonings. Michael Kim, MPH April 30, 2012

Prescription Drug Monitoring Programs: A State Policy to Address Prescription Opioid Poisonings. Michael Kim, MPH April 30, 2012 Prescription Drug Monitoring Programs: A State Policy to Address Prescription Opioid Poisonings Michael Kim, MPH April 30, 2012 Overview 1. Prescription Opioid Abuse and Poisoning 2. Prescription Drug

More information

Department of Health and Human Services Substance Abuse and Mental Health Services Administration

Department of Health and Human Services Substance Abuse and Mental Health Services Administration Department of Health and Human Services Substance Abuse and Mental Health Services Administration PPHF-2012-Cooperative Agreements for Prescription Drug Monitoring Program (PDMP) Electronic Health Record

More information

Mayor s Task Force On Prescription Painkiller Abuse

Mayor s Task Force On Prescription Painkiller Abuse Mayor s Task Force On Prescription Painkiller Abuse Interim Report January 2013 BACKGROUND In response to a growing epidemic, in late 2011 Mayor Bloomberg created the multi-agency Task Force on Prescription

More information

The Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

The Prescription Opioid and Heroin Crisis: An Epidemic of Addiction The Prescription Opioid and Heroin Crisis: An Epidemic of Addiction Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation Inc. Executive Director, Physicians for Responsible Opioid Prescribing

More information

Opioids and the Injured Worker Tools for Successful Outcomes

Opioids and the Injured Worker Tools for Successful Outcomes Opioids and the Injured Worker Tools for Successful Outcomes Tim Pokorney, RPh Director, Clinical Express Scripts Workers' Compensation Division Goals and Objectives Alarming statistics for narcotic utilization,

More information

NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS

NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS NOTICE REQUIREMENTS FOR PRESCRIPTION MONITORING PROGRAMS This project was supported by Grant No. G1299ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this

More information

Prescription Drug Monitoring Programs Bill Status Update

Prescription Drug Monitoring Programs Bill Status Update Prescription Drug Monitoring Programs Bill Status Update Research current through February 24, 2015. This project was supported by Grant No. G1399ONDCP03A, awarded by the Office of National Drug Control

More information

Implementation of Florida s PDMP. Rebecca Poston Program Manager

Implementation of Florida s PDMP. Rebecca Poston Program Manager Implementation of Florida s PDMP Rebecca Poston Program Manager Disclaimer I have no relevant financial relationships or commercial interest in the content presented in this program. Learning Objectives:

More information

2. PRESCRIPTION DRUG MONITORING PROGRAMS (PDMPs)

2. PRESCRIPTION DRUG MONITORING PROGRAMS (PDMPs) NATIONAL CONFERENCE OF INSURANCE LEGISLATORS (NCOIL) PROPOSED BEST PRACTICES TO ADDRESS OPIOID ABUSE, MISUSE & DIVERSION To be considered by the NCOIL Workers Compensation Insurance Committee on July 12,

More information

TABLE OF CONTENTS CHAPTER 8 PRESCRIPTION DRUG MONITORING PROGRAM

TABLE OF CONTENTS CHAPTER 8 PRESCRIPTION DRUG MONITORING PROGRAM TABLE OF CONTENTS CHAPTER 8 PRESCRIPTION DRUG MONITORING PROGRAM Section 1. Authority 8-1 Section 2. Transmission of Information Regarding Dispensing of Controlled Substances to Certain Persons 8-1 Section

More information

CAPITOL research. Interstate Information Sharing: Prescription Drug Monitoring Programs

CAPITOL research. Interstate Information Sharing: Prescription Drug Monitoring Programs The Council of State governments CAPITOL research APRIL 00 Prescription Drug Monitoring Interstate Information Sharing: Prescription Drug Monitoring Programs The Council of State Governments Misuse of

More information

Enhancing Access to Prescription Drug Monitoring Programs Using Health Information Technology: Work Group Recommendations

Enhancing Access to Prescription Drug Monitoring Programs Using Health Information Technology: Work Group Recommendations Prepared for Office of the National Coordinator for Health Information Technology, in partnership with the Substance Abuse and Mental Health Services Administration Enhancing Access to Prescription Drug

More information

Federal & State Laws Related to Prescribing Controlled Substances

Federal & State Laws Related to Prescribing Controlled Substances Federal & State Laws Related to Prescribing Controlled Substances Richard E. Moses, D.O., J.D., F.A.C.O.I. American College of Osteopathic Internists 2012 Annual Convention & Scientific Sessions Renaissance

More information

FDA Advisory Committee Hearing on Potential Rescheduling of Hydrocodone: Pharmacist and Pharmacy Issues to Consider

FDA Advisory Committee Hearing on Potential Rescheduling of Hydrocodone: Pharmacist and Pharmacy Issues to Consider FDA Advisory Committee Hearing on Potential Rescheduling of Hydrocodone: Pharmacist and Pharmacy Issues to Consider January 24, 2013 FDA White Oak Campus Steve Simenson, BPharm, FAPhA, DPNAP APhA President

More information

ACTION PLAN FOR IMPROVING ACCESS TO PRESCRIPTION DRUG MONITORING PROGRAMS THROUGH HEALTH INFORMATION TECHNOLOGY

ACTION PLAN FOR IMPROVING ACCESS TO PRESCRIPTION DRUG MONITORING PROGRAMS THROUGH HEALTH INFORMATION TECHNOLOGY ACTION PLAN FOR IMPROVING ACCESS TO PRESCRIPTION DRUG MONITORING PROGRAMS THROUGH HEALTH INFORMATION TECHNOLOGY Presented to The Behavioral Health Coordinating Committee, Department of Health and Human

More information

Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS)

Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS) Initial REMS approval: 02/2013 Most recent modification: 06/2015 Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS) This REMS applies

More information

Technical Assistance Guide. PDMP Suggested Practices to Ensure Pharmacy Compliance and Improve Data Integrity

Technical Assistance Guide. PDMP Suggested Practices to Ensure Pharmacy Compliance and Improve Data Integrity Technical Assistance Guide PDMP Suggested Practices to Ensure Pharmacy Compliance and Improve Data Integrity This project was supported by Grant No. 2011-PM-BX-K001 awarded by the Bureau of Justice Assistance.

More information

Prescription Drug Abuse and NASPER Harold Rogers Prescription Drug Monitoring Program June 30, 2010 Washington, DC

Prescription Drug Abuse and NASPER Harold Rogers Prescription Drug Monitoring Program June 30, 2010 Washington, DC Prescription Drug Abuse and NASPER Harold Rogers Prescription Drug Monitoring Program June 30, 2010 Washington, DC Nick Reuter Division of Pharmacologic Therapy Substance Abuse and Mental Health Services

More information

Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas

Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas David Lakey, MD Commissioner, Department of State Health Services Lauren Lacefield Lewis Assistant Commissioner,

More information

REFERENCE ACTION ANALYST STAFF DIRECTOR or BUDGET/POLICY CHIEF. 1) Health Quality Subcommittee 9 Y, 2 N Poche O'Callaghan SUMMARY ANALYSIS

REFERENCE ACTION ANALYST STAFF DIRECTOR or BUDGET/POLICY CHIEF. 1) Health Quality Subcommittee 9 Y, 2 N Poche O'Callaghan SUMMARY ANALYSIS HOUSE OF REPRESENTATIVES STAFF ANALYSIS BILL #: HB 1381 Prescription Drug Monitoring Program SPONSOR(S): Davis TIED BILLS: IDEN./SIM. BILLS: REFERENCE ACTION ANALYST STAFF DIRECTOR or BUDGET/POLICY CHIEF

More information

Palmer MacKie, MD MS Director, Integrative Pain Program, Eskenazi Department of Medicine, IUSOM

Palmer MacKie, MD MS Director, Integrative Pain Program, Eskenazi Department of Medicine, IUSOM Palmer MacKie, MD MS Director, Integrative Pain Program, Eskenazi Department of Medicine, IUSOM Attorney General s Prescription Drug Abuse Task Force Member AIT Laboratories Advisory Board In 2009, 44%

More information

Technical Assistance Guide No. 04-13 Funding Options for Prescription Drug Monitoring Programs

Technical Assistance Guide No. 04-13 Funding Options for Prescription Drug Monitoring Programs Technical Assistance Guide No. 04-13 Funding Options for Prescription Drug Monitoring Programs July 3, 2013 Introduction Over the past ten years, prescription drug monitoring programs (PDMPs) have proliferated

More information

The Role of Prescription Drug Monitoring Programs in Combatting Controlled Substance Abuse

The Role of Prescription Drug Monitoring Programs in Combatting Controlled Substance Abuse The Role of Prescription Drug Monitoring Programs in Combatting Controlled Substance Abuse Amanda J. Ward, PharmD, CGP Pharmacist Consultant Drug Enforcement and Professional Practices Branch Office of

More information

PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE

PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE PRESCRIPTION DRUG ABUSE: THE NATIONAL PERSPECTIVE May 19, 2012 National Association Boards of Pharmacy Annual Meeting Gil Kerlikowske, Director White House Office of National Drug Control Policy ONDCP

More information

Trends of Opioid Misuse and Diversion: Lessons from the United States

Trends of Opioid Misuse and Diversion: Lessons from the United States Trends of Opioid Misuse and Diversion: Lessons from the United States 31 October 2012 Richard C. Dart, MD, PhD Director Rocky Mountain Poison and Drug Center Professor - University of Colorado, Department

More information

CDC s Prevention Efforts to Address Prescription Opioid Epidemic

CDC s Prevention Efforts to Address Prescription Opioid Epidemic CDC s Prevention Efforts to Address Prescription Opioid Epidemic Jan Losby, PhD, MSW Lead, Prescription Drug Overdose Health Systems and State Support Team Division of Unintentional Injury Prevention NASBO

More information

Prescription Monitoring Programs: Creating a National Network

Prescription Monitoring Programs: Creating a National Network Prescription Monitoring Programs: Creating a National Network Danna E. Droz, JD, RPH PMP Liaison ddroz@nabp.net 847/391-4508 United States Drug Enforcement Administration National Conference on Pharmaceutical

More information

2.1 Staying Clear of the Law and Addiction: Nevada s Pre- Criminal Intervention Program

2.1 Staying Clear of the Law and Addiction: Nevada s Pre- Criminal Intervention Program PMP Center of Excellence Notes from the Field 2.1 Staying Clear of the Law and Addiction: Nevada s Pre- Criminal Intervention Program January 2011 This project was supported by Grant No. 2006-DG-BX-K071

More information